Rxivist logo

Effective clinical intervention strategies for COVID-19 are urgently needed. Although several clinical trials have evaluated the use of convalescent plasma containing virus-neutralizing antibodies, the effectiveness has not been proven. We show that hamsters treated with a high dose of human convalescent plasma or a monoclonal antibody were protected against weight loss showing reduced pneumonia and pulmonary virus replication compared to control animals. However, a ten-fold lower dose of convalescent plasma showed no protective effect. Thus, variable and relatively low levels of virus neutralizing antibodies in convalescent plasma may limit their use for effective antiviral therapy, favouring concentrated, purified (monoclonal) antibodies. ### Competing Interest Statement A patent application has been filed for antibody 47D11 targeting SARS-CoV-2 (United Kingdom patent application no. 2003632.3; patent applicants: Utrecht University, Erasmus Medical Center and Harbour BioMed). Others declare no competing interests.

Download data

  • Downloaded 1,505 times
  • Download rankings, all-time:
    • Site-wide: 7,046 out of 105,834
    • In microbiology: 479 out of 9,238
  • Year to date:
    • Site-wide: 1,554 out of 105,834
  • Since beginning of last month:
    • Site-wide: 2,643 out of 105,834

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)